Vitality Watch

Dossier pubmed observational 30-jul-2026
Human cohort, case-control, or epidemiological association

Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses.

Key claim: Genetically predicted higher physiological GLP-1 combined with lower GIP is associated with complementary reductions in obesity, CVD, venous thromboembolism, and hepatic-event risk, with body weight a plausible mediator and no bone-metabolism harm signal.

Abstract

BACKGROUND: The long-term health effects of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) remain unclear. Most importantly, it is highly controversial whether GIP agonists vs. antagonists should be developed and what their effects and/or potential side effects would be in the clinic. Further investigation is needed to explore the effects of GIP lowering alone or in combination with GLP-1 enhancing. Tree-structured phenotypic modeling (TreeWAS) and factorial Mendelian randomization (MR) analyses are valuable in this context, even though the highest circulating GLP-1 levels may reflect only a minimum activation i.e. levels achieved with pharmacological intervention with dipeptidyl peptidase 4 (DPP-4) inhibitors and not GLP-1 receptor agonists (GLP-1 RAs) which achieve much higher levels. METHODS: TreeWAS was first conducted to map associations of GLP-1 or GIP levels with a broad range of disease outcomes among 385,917 UK Biobank participants. Disease-trajectory analysis was applied to characterize temporal patterns of co-occurrence of multiple comorbidities related to GLP-1 or GIP or both. Subsequently, factorial MR was performed to investigate the joint effects of GLP-1 and GIP on the associated health outcomes. Finally, mediation analysis was employed to explore the underlying mechanisms through which GLP-1 and GIP exert their effects. RESULTS: TreeWAS analysis revealed associations of elevated genetically predicted GLP-1 levels, even within the normal range, with decreased risk of metabolic diseases (e.g. type 2 diabetes) and polyarthropathies (e.g. gout). While genetically determined low GIP levels were linked to reduced risk of obesity, metabolic diseases (e.g. disorders of lipoprotein metabolism and other lipidaemias), digestive/hepatic and cardiometabolic diseases. Consistently, disease-trajectory analysis identified four major comorbidity clusters among individuals with genetically proxied physiologically lower GLP-1 and higher GIP levels, primarily involving metabolic diseases (e.g. type 2 diabetes), musculoskeletal system diseases (e.g. gout), gastrointestinal and urinary system disorders. Furthermore, the combined exposure to genetically predicted higher GLP-1 and lower GIP levels were associated with complementary and additive reductions in the risk of obesity (HR = 0.93, 95%CI: 0.88-0.99, p = 0.018), CVD (HR = 0.97, 95%CI: 0.94-0.99, p = 0.021), venous thromboembolism (VTE) (HR = 0.91, 95%CI: 0.83-1.00, p = 0.039), and multiplicative effects on composite hepatic events (CHEs) (HR = 0.88, 95%CI: 0.77-0.99, p = 0.040). No side effects on bone metabolism were identified. Finally, mediation analysis revealed that genetically predicted lower physiological GIP levels were associated with lower risk of obesity, CVD, VTE, overall and cardiovascular-specific mortality, with body weight consistent with a potential mediating role in exploratory decomposition analyses. CONCLUSIONS: Our genetic findings are consistent with the hypothesis that GLP-1 levels in the higher physiological range and GIP levels in the lower physiological range, individually and jointly, may be associated with lower body weight and improved cardiometabolic and liver phenotypes, while these observations warrant mechanistic and clinical investigation.

Why this matters

Pharmacological debate over whether next-generation incretin drugs should agonize or antagonize GIP currently hinges on mechanism and trial-level body-composition signals; this Mendelian randomization adds human genetic evidence that lifelong higher GLP-1 plus lower GIP tracks with lower obesity, CVD, VTE, and hepatic-event risk without a bone-metabolism harm signal. In this area’s nutrition-and-metabolic-control frame, it reinforces endogenous incretin tone as a plausible lever on cardiometabolic aging while remaining short of outcome-trial evidence.

Source

Link

Briefing card

Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses.
Stage: observational · pubmed · 30-jul-2026

If you are tracking the tirzepatide-versus-GIP-antagonist debate, this genetic analysis points toward lower GIP (not higher) as the complementary direction to GLP-1 for weight and cardiometabolic risk.

Genetically predicted higher physiological GLP-1 combined with lower GIP is associated with complementary reductions in obesity, CVD, venous thromboembolism, and hepatic-event risk, with body weight a plausible mediator and no bone-metabolism harm signal.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.metabol.2026.156711

build build 880 · 2bcef25 · 2026-11-18